Latest Breaking News On - Segal trials - Page 1 : vimarsana.com

RECORD-BREAKING TURNOUT AT NAMI MIAMI-DADE'S FOURTH ANNUAL WALK FOR MENTAL HEALTH AWARENESS

Over 3,7000 Participants Gathered at ZOO Miami, Raising $385,000 and Highlighting the Growing Demand for Mental Health Services in Miami-Dade and the Florida Keys With more than 3,700 participants and 265 teams, the Fourth Annual Walk for Mental Health Awareness hosted by the National Alliance on Mental Illness (NAMI) Miami-Dade on Saturday, May 18 at

3 Simple Ways To Become A Better Clinical Researcher

See, do, and listen. Simple right? John Nocero, Ph.D., and Andrea Bordonaro, MAT, advise clinical researchers on these three easy ways to improving...

Psychiatry Month in Review: April 2024

This month in review features top psychiatry news in the pipeline, FDA approvals, and a piece for autism awareness month.

New Data Demonstrates KarXT's Positive Long-Term Metabolic Profile

Learn more about the latest data on KarXT, which is posed to be the first new pharmacological treatment for schizophrenia.

'Escalating tension' in Judge Cannon's orders for Trump's classified documents case

Former lead investigator for the January 6th Select Committee Tim Heaphy and MSNBC legal correspondent List Rubin discuss the latest updates for each of former President Donald Trump’s legal trials including the classified documents case, civil fraud trial, and hush money hearing.

KarXT Effective in Improving Schizophrenia Symptoms at 52 Weeks

EMERGENT-3 trial showed xanomeline-trospium was effective in improving schizophrenia symptoms at 52 weeks, for participants who took either placebo or KarXT in acute trials.

Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

 KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment A majority of patients ...

Channel Your Inner Child To Become A Better Clinical Research Professional

Peer-Reviewed EMERGENT-2 Trial Data Supports Xanomeline-Trospium for Schizophrenia

In a phase 3 EMERGENT-2 trial, the study found 55% of participants with schizophrenia taking xanomeline-trospium had a ≥30% improvement from baseline to week 5, compared to the placebo group.